13 year old Asian male
Switched to ALTUVIIIO: October 2023
Aaron, who has severe hemophilia A, presented for a comprehensive-care visit. Aaron maintains an active lifestyle, self-administers, and wanted to reduce the frequency of infusions.
Patient Information
Presented for a comprehensive care visit, with a desire to reduce the frequency of infusions while on twice-weekly EHL prophylaxis
- Born in China (adopted in 2017); diagnosis history is unknown
- Treated with SHL prophylaxis until early 2017 (dosing unknown)
- Experienced possible right-ankle hemarthrosis while living in China (treatment unclear)
- Surgical correction of VSD (2017)
- Unknown, due to adoption
- BP: 123/69
- BMI: 19.22
- HR: 64
- No significant findings on physical exam
- Inhibitor titer negative
Aaron’s Path to High Sustained Factor Replacement Therapy, ALTUVIIIO
Diagnosis
- Aaron’s diagnosis history is unknown due to his adoption, but it was possibly due to right-ankle hemarthrosis while in China
After diagnosis
- Aaron has tried both SHL and EHL therapies without complication, along with perioperative factor treatment
- While in China, until 2017, he was on twice weekly SHL prophylaxis (dose unknown)
- He switched to twice weekly EHL prophylaxis (40-50 IU/kg) in May 2017 upon adoption, with no reported joint or muscle bleeds while on EHL therapy
- Aaron received perioperative EHL therapy in September 2017, 1000 IU prior to cardiac catheterization, and in November 2017, 1500 IU for 5 days starting on day of procedure for surgical correction of VSD (estimated patient weight was 83 pounds at the time of both procedures)
Before ALTUVIIIO
- Aaron presented for comprehensive care visit
- Possible history of right-ankle hemarthrosis while living in China but treatment is unclear
- Treatment regimen: EHL prophylaxis, 40 to 50 IU/kg twice-weekly with excellent adherence
Considering the switch
The comprehensive care team, Aaron, and his family discussed Aaron’s:
- Physical activity as a flag-football player at school
- Desire to decrease infusion frequency
- Desire for Factor VIII replacement therapy only
The care team, Aaron, and his family determined ALTUVIIIO was the best fit for him to:
- Reduce infusion frequency1
- Maintain Factor VIII levels closer to normal1
After ALTUVIIIO
Switched to ALTUVIIIO: October 2023
- Since starting ALTUVIIIO prophylaxis, Aaron has normal to near-normal Factor VIII1 levels (>40%) for >3 days of the week1 and has experienced 0 breakthrough bleeds
Do you have patients like Aaron?
If so, it may be worth it to consider the following:
How good is good enough?
Would you consider a patient like Aaron to be doing okay on their current treatment?
Choosing the right treatment
How would you discuss switching to a treatment option like ALTUVIIIO with patients like Aaron?
Unlocking high sustained factor levels
Do you think high sustained factor levels and once-weekly dosing with ALTUVIIIO1 could benefit your patients like Aaron?
BMI=body mass index; BP=blood pressure; EHL=extended half-life; HR=heart rate; IU=international unit; SHL=standard half-life; VSD=ventricular septal defect.
Other ALTUVIIIO patients who made the switch!
Meet Henry
A 14 year old student and avid baseball player with severe hemophilia A, previously treating with factor-mimetic prophylaxis and an on-demand SHL therapy.
Meet Sean
A 39 year old technical support professional with severe hemophilia A who underwent a total knee arthroplasty.
Indication
References: 1. ALTUVIIIO Prescribing Information, Bioverativ Therapeutics Inc. Waltham, MA.
